latest news releases from the newsroom
OncoGenex Pharmaceuticals, Inc.
Sonus Pharmaceuticals Announces Receipt of NASDAQ Notification
BOTHELL, Wash., Nov. 7, 2007 (PRIME NEWSWIRE) -- Sonus Pharmaceuticals, Inc. (Nasdaq:SNUS) today announced that it has received a notice from The Nasdaq Stock Market ("Nasdaq") dated November 5, 2007, indicating that the Company does not comply with the $1.00 minimum bid price requirement for continued listing under Marketplace Rule 4450(a)(5). Therefore, in accordance with Marketplace Rule 4450(e)(2), the Company has 180 calendar days, or until May 5, 2008, to regain compliance. If, at any time, the bid price of the Company's stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will notify the Company that it has achieved compliance with the Rule. If the Company does not regain compliance with the Rule by May 5, 2008, the Company understands that Nasdaq's Staff will provide written notification that its common stock will be delisted.
AMERCO / U-Haul
Amerco Reports Second Quarter Fiscal 2008 Financial Results
RENO, Nev., Nov. 7, 2007 (PRIME NEWSWIRE) -- AMERCO (Nasdaq:UHAL), parent of U-Haul International, Inc., North America's largest do-it-yourself moving and storage operator, today reported net earnings available to common shareholders for its second quarter ending September 30, 2007, of $47.2 million, or $2.39 per share, compared with net earnings of $57.3 million, or $2.74 per share, for the same period last year. Included in the results for September 30, 2006 was a nonrecurring after-tax charge of $0.20 per share associated with the Company's second-quarter debt amendment. Taking into account the nonrecurring after-tax charge, adjusted earnings were $2.94 per share for the three months ending September 30, 2006.
Medicis Pharmaceutical Corporation
Medicis Reports Third Quarter 2007 Financial Results
SCOTTSDALE, Ariz., Nov. 7, 2007 (PRIME NEWSWIRE) -- Medicis (NYSE:MRX) today announced non-U.S. generally accepted accounting principles ("non-GAAP") revenue for the three months ended September 30, 2007 of approximately $120.4 million, compared to approximately $90.0 million for the three months ended September 30, 2006, representing a year-over-year increase of approximately 34%. This increase was primarily due to strength in our acne products, namely SOLODYN(R) and ZIANA(R). Non-GAAP net income for the three months ended September 30, 2007 was approximately $24.1 million, or approximately $0.36 per diluted share, compared to non-GAAP net income of $12.9 million, or $0.21 per diluted share, for the three months ended September 30, 2006.
State Bancorp, Inc.
State Bancorp, Inc. President and CEO Featured in NASDAQ CEO Signature Series Interview
JERICHO, N.Y., Nov. 7, 2007 (PRIME NEWSWIRE) -- State Bancorp, Inc. President and CEO, Tom O'Brien, was interviewed as a featured guest on NASDAQ's CEO Signature Series this Tuesday, November 6, 2007. The interview, conducted by Sasha Salama, a veteran business journalist, covered State Bancorp's strategy, current financials, and forecast for the industry. The webcast will be on the following sites for the next 30 days: NASDAQ.com, NASDAQ.net, investors.NASDAQ.com, streetevents.com, factset.com/callstreet, vcall.com, and investorcalendar.com. The webcast will also be available and archived on the State Bancorp, Inc. website. To access, log on to www.statebankofli.com, choose the Investor Relations section, select Events and Presentations and click on the NASDAQ CEO Signature Series link.